drugset / Trial / NCT02595008

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

NCT02595008 ↗

Phase 2 Completed 24 enrolled Sun Pharmaceutical Industries, Inc.
NaSingle-groupOpen-labelTreatment

Summary

this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.

Timeline

Start
2015-08-28
Primary completion
2017-02-22
Completion
2017-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject DSXS Unknown — —

Indications